Inventor · disambiguated record
Erik W. Bush
Also filed as: BUSH ERIK · BUSH ERIK W
8 granted patents·10 pending applications·6 citations·filing 2003–2024
77Inventor score
Top patents by PatentIndex Score
18 records- 0186US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 0282US11597701B2Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·2 cites·24 claims
- 0381US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 0471US2022090077A1RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0569US12173086B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·15 claims
- 0669US11214802B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·42 claims
- 0767US2024076270A1Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0866US2025034578A1Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-productsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0963US2023265437A1RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1060US12365897B2RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·18 claims
- 1160US2023013022A1RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1256US12486502B2RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 1351US2005182011A1Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failureFiled 2004·Application pending·0 cites
- 1446US2008031818A1Use of Modulators of a Novel Form of Muscle Selective Calcineurin Interacting Protein (Mcip-1-38) as a Treatment for Cardiovascular DiseasesGILEAD COLORADO INC·Filed 2005·Application pending·0 cites
- 1545US2007015777A1Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the HeartMYOGEN INC·Filed 2006·Application pending·0 cites
- 1643US2005265999A1Modulation of 5-HT2 receptors as a treatment for cardiovascular diseasesUNIV TEXAS·Filed 2004·Application pending·0 cites
- 1740US2003186289A1Model cell systems for screening of anti-hypertrophic therapeuticsMYOGEN INC·Filed 2003·Application pending·0 cites
- 1835US7638519B2Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular diseaseMYOGEN INC·Filed 2004·Granted Dec 29, 2009·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Erik W. Bush files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →